Effects of BAY w 6228 on coagulation and fibrinolytic systems in patients with hyperlipidemia

Japanese Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 9, 1996, Pages 243-252

  Wada, Hideo ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ARTICLE; BLOOD CLOTTING; DOSE RESPONSE; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; PATIENT COMPLIANCE;

EID: 0029854436     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rokitansky CV : A manual of pathologic anatomy, p 3, The Sydenham Society, London, 1952
2. Ross R, Glomset JA : The pathogenesis of atherosclerosis. N Eng J Med 295 : 369-377, 1976
3. Ross R : The pathogenesis of atherosclerosis an update. N Eng J Med 314 : 488-500, 1986
4. Christakis G et al : The anti-coronary club. Am J Publ Health 56 : 299-314, 1966
5. Christakis G et al : Effect of the anti-coronary club program on coronary heart disease risk-factor status. JAMA 198 : 597-604, 1966
6. Kannel WB et al : Serum cholesterol, lipoproteins, and the risk of coronary heart disease ; The Framingham study. Ann Intern Med 74 : 1-12, 1971
7. Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results ( I ) ; Reduction in incidence of coronary heart disease. JAMA 251 : 351-364, 1984
8. Mori Y et al : Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis : Effect of probucol on coagulation. Thromb Haemostas 61 : 140-143, 1989
9. Wada H et al : Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hema 44 : 112-116, 1993
10. Hilmar B et al : Pharmacology of the new highly potent HMG-CoA reductase inhibitor cerivastatin (BAY w 6228). Atherosclerosis (in press)
11. Friedewald WT et al : Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 : 499-502, 1972
12. Morito T : Evaluation and significance of the clotpromoting potential of urokinase. Mie Med J 31 : 227-243, 1981
13. MOOK 19:71-81, 1982
14. Broze GJ Jr et al : Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 13 : 6001-6004, 1988